Payment overview · 2025
General Payments
$1,300.67
63 reported records · 20 companies
Healthcare provider profile · identity verified
David H Montgomery, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · OAKLAND, NJ · NPI 1124108808
Verified facts
What the public records show
CMS Open Payments records show David H Montgomery, MD received $1,300.67 in general payments during 2025 across 63 reported records.
Novartis Pharmaceuticals Corporation accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Nexletol, Ozempic, Wegovy.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 838 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 838 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $218.71 | 16.8% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $179.20 | 13.8% | 11 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $140.20 | 10.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $108.03 | 8.3% | 6 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $87.39 | 6.7% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $62.78 | 4.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.78 | 4.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.93 | 4.1% | 3 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $52.29 | 4.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.01 | 3.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.83 | 3.8% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $42.98 | 3.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.94 | 2.9% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.02 | 2.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.93 | 1.9% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $24.00 | 1.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.44 | 1.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.05 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.78 | 1.4% | 1 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $16.38 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,300.67 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $218.71 | 12 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $151.34 | 9 | 2025 |
Source payment records
|
|||||
| Technical Education MRI Normalized: technical education mri |
Device | Philips North America LLC | $140.20 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $89.11 | 5 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $87.39 | 5 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $68.20 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.78 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $52.93 | 3 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $52.29 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $50.01 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $49.83 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.83 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.94 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $33.02 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.86 | 2 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 838 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 140 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 52 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 58 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 40 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
838 | 183 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 40 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
96 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
58 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
838 | 183 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1117 | 332 |
| Metoprolol Succinate | Metoprolol Succinate | 1024 | 304 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 990 | 291 |
| Atorvastatin Calcium | Atorvastatin Calcium | 984 | 287 |
| Ezetimibe | Ezetimibe | 956 | 297 |
| Eliquis | Apixaban | 838 | 183 |
| Valsartan | Valsartan | 677 | 196 |
| Simvastatin | Simvastatin | 594 | 164 |
| Pravastatin Sodium | Pravastatin Sodium | 546 | 175 |
| Hydrochlorothiazide | Hydrochlorothiazide | 395 | 125 |
| Spironolactone | Spironolactone | 385 | 118 |
| Losartan Potassium | Losartan Potassium | 358 | 103 |
| Lisinopril | Lisinopril | 354 | 104 |
| Metoprolol Tartrate | Metoprolol Tartrate | 296 | 90 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 281 | 86 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 258 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 237 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 222 | 70 |
| Torsemide | Torsemide | 208 | 71 |
| Carvedilol | Carvedilol | 188 | 55 |
| Repatha Sureclick | Evolocumab | 170 | 44 |
| Nebivolol Hcl | Nebivolol Hcl | 165 | 54 |
| Xarelto | Rivaroxaban | 163 | 37 |
| Furosemide | Furosemide | 158 | 51 |
| Famotidine | Famotidine | 151 | 64 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 145 | 46 |
| Jardiance | Empagliflozin | 140 | 40 |
| Atenolol | Atenolol | 130 | 35 |
| Ramipril | Ramipril | 129 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 121 | 35 |
| Alprazolam | Alprazolam | 114 | 52 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 113 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 112 | 33 |
| Metformin Hcl | Metformin Hcl | 112 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 37 |
| Allopurinol | Allopurinol | 105 | 32 |
| Warfarin Sodium | Warfarin Sodium | 102 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 101 | 29 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 98 | 27 |
| Benazepril Hcl | Benazepril Hcl | 98 | 27 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 97 | 24 |
| Entresto | Sacubitril/Valsartan | 96 | 21 |
| Irbesartan | Irbesartan | 78 | 21 |
| Omeprazole | Omeprazole | 78 | 27 |
| Sertraline Hcl | Sertraline Hcl | 77 | 26 |
| Ozempic | Semaglutide | 75 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 18 |
| Potassium Chloride | Potassium Chloride | 59 | 23 |
| Alendronate Sodium | Alendronate Sodium | 58 | 15 |
| Wegovy | Semaglutide | 58 | 14 |
| Fenofibrate | Fenofibrate | 56 | 16 |
| Eplerenone | Eplerenone | 55 | 17 |
| Nexletol | Bempedoic Acid | 52 | 16 |
| Farxiga | Dapagliflozin Propanediol | 48 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 44 | 12 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 43 | 12 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 43 | 13 |
| Amoxicillin | Amoxicillin | 39 | 26 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | 17 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 36 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 35 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 33 | suppressed |
| Gabapentin | Gabapentin | 33 | 15 |
| Midodrine Hcl | Midodrine Hcl | 32 | 12 |
| Praluent Pen | Alirocumab | 31 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 11 |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 25 |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Colchicine | Colchicine | 26 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 26 | suppressed |
| Diazepam | Diazepam | 24 | 11 |
| Digoxin | Digoxin | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 18 |
| Brilinta | Ticagrelor | 22 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | suppressed |
| Dofetilide | Dofetilide | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Livalo | Pitavastatin Calcium | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Silodosin | Silodosin | 16 | suppressed |
| Verelan Pm | Verapamil Hcl | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,300.67 · 63 records | Novartis Pharmaceuticals Corporation | AMVUTTRA, Attruby, BIOMONITOR, CAMZYOS, CARDIVA VASCADE MVP VVCS 6-12F, Cleerly Ischemia, Cleerly Labs, Cologuard Collection Kit, ELIQUIS, JARDIANCE, Kerendia, LEQVIO, NEXLETOL, NURTEC ODT, Ozempic, REPATHA, Rybelsus, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, Technical Education MRI, VERQUVO, VYNDAQEL, WATCHMAN FLX, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error